Understanding barriers and delays in diagnosing anal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study analyzes care pathways in 300 patients with anal squamous cell carcinoma to identify barriers and delays in diagnosis and to evaluate the impact of screening and access to care. It will quantify diagnostic waiting times, examine whether cancers were found through screening, and assess the proportion of eligible patients who did not benefit from screening. The research also investigates patient reluctance, socioeconomic influences, and knowledge of the link between HPV and anal cancer to inform targeted education efforts. The goal is to improve care pathways, raise awareness among the public and healthcare professionals, and promote earlier diagnosis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Male or female ≥ 18 years
2. Histologically proven invasive or microinvasive squamous cell carcinoma of the anus
3. Having read and understood the information letter provided, either:

   i. After disclosure of the diagnosis, or ii. At the latest 6 months after initiation of treatment (surgical excision, radiotherapy, or chemoradiotherapy)
4. Affiliated with a social security system

Exclusion Criteria:

1. Refusal to participate in the protocol
2. Other histological types: lymphoma, adenocarcinoma, neuroendocrine tumor, etc.
3. Time since treatment initiation greater than 6 months
4. Protected persons (pregnant women, breastfeeding women, individuals under guardianship or curators, minors, persons deprived of liberty, or persons unable to express informed consent).

Where it's running

• CHU Angers
  Angers, France Recruiting
• Clinique Belharra
  Bayonne, France Recruiting
• CH Béthune
  Beuvry, France Recruiting
• CH du Haut Anjou
  Château-Gontier, France Recruiting
• Polyclinique du Parc Vivalto
  Cholet, France Recruiting
• Centre Hospitalier Intercommunal de Créteil
  Créteil, France Recruiting

Study contacts

• Study coordinator: Camille JUNG, PhD
• Email: camille.jung@chicreteil.fr
• Phone: (0)1 57 02 50 00

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Investigating BCA101 for advanced solid tumors driven by EGFR

  This study is testing a new treatment called BCA101 to see if it can help people with advanced solid tumors that are driven by EGFR, especially those who haven't responded to other therapies.

  Recruiting at 21 sites Phase 1 Bicara Therapeutics · La Jolla, California and 20 other locations · NCT04429542

• Neoadjuvant chemotherapy plus tislelizumab for advanced squamous cell cancer of the external auditory canal

  This will test whether giving tislelizumab with induction chemotherapy before surgery helps people with locally advanced squamous cell carcinoma of the external auditory canal.

  Recruiting Phase 2 Eye & ENT Hospital of Fudan University · Shanghai, Shanghai Municipality · NCT07370337

• Blood ctDNA testing to guide follow-up and treatment for HPV-related cervical and anal canal cancers.

  This study will test whether regular blood tests for HPV ctDNA can guide follow-up and whether giving pembrolizumab after radiotherapy helps people with HPV-related cervical or anal canal cancer who still have positive ctDNA.

  Recruiting Phase 2 Instituto do Cancer do Estado de São Paulo · São Paulo · NCT06640283

• Screening methods for high-risk anal cancer patients

  This study is testing new ways to screen for early signs of anal cancer in high-risk people, especially those living with HIV, to help improve their health outcomes.

  Recruiting at 4 sites Emory University · Miami, Florida and 3 other locations · NCT06628570

• Immunotherapy using E7 TCR-T cells for HPV-related cancers

  This study is testing a new immunotherapy using E7 TCR-T cells to see if it can help people with advanced HPV-related cancers like cervical and throat cancer feel better and improve their health.

  Recruiting at 3 sites Phase 2 Rutgers, The State University of New Jersey · Bethesda, Maryland and 2 other locations · NCT05686226

• E7 T-cell therapy for advanced HPV-related cancers

  This study is testing a new treatment using specially modified immune cells to see if it can help people with advanced cancers linked to HPV feel better and live longer.

  Recruiting at 2 sites Phase 1/2 Rutgers, The State University of New Jersey · New Brunswick, New Jersey and 1 other locations · NCT05639972

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.